Halozyme Reports Second Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Halozyme Therapeutics (HALO) Tops Q2 EPS by 1c
August 8, 2017 4:53 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $31.76 million.
GUIDANCE:
Halozyme Therapeutics sees FY2017 revenue of $115-130 million, versus the consensus of... More
